CoChat

DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer

Open access

Published version of a preprint

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Although ovarian cancer has a low incidence rate, it remains the most deadly gynecologic malignancy. Previous work has demonstrated that the DNMTi 5-Azacytidine (5AZA-C) activates type I interferon signaling to increase IFNγ+ T cells and natural killer (NK) cells and reduce the percentage of macrophages in the tumor microenvironment. To improve the efficacy of epigenetic therapy, we hypothesized that the addition of α-difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, may further decrease immunosuppressive cell populations improving outcome. We tested this hypothesis in an immunocompetent mouse model for ovarian cancer and found that in vivo, 5AZA-C and DFMO, either alone or in combination, significantly increased survival, decreased tumor burden, and caused recruitment of activated (IFNγ+) CD4+ T cells, CD8+ T cells, and NK cells. The combination therapy had a striking increase in survival when compared with single-agent treatment, despite a smaller difference in recruited lymphocytes. Instead, combination therapy led to a significant decrease in immunosuppressive cells such as M2 polarized macrophages and an increase in tumor-killing M1 macrophages. In this model, depletion of macrophages with a CSF1R-blocking antibody reduced the efficacy of 5AZA-C + DFMO treatment and resulted in fewer M1 macrophages in the tumor microenvironment. These observations suggest our novel combination therapy modifies macrophage polarization in the tumor microenvironment, recruiting M1 macrophages and prolonging survival. Significance: Combined epigenetic and polyamine-reducing therapy stimulates M1 macrophage polarization in the tumor microenvironment of an ovarian cancer mouse model, resulting in decreased tumor burden and prolonged survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-18-4018

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 104

Metadata

Authors
Travers, M., Brown, S. M., Dunworth, M., Holbert, C. E., Wiehagen, K. R., Bachman, K. E., Foley, J. R., Stone, M. L., Baylin, S. B., Casero, R. A., & Zahnow, C. A.
Affiliations
  • Johns Hopkins University (US)
  • 2Janssen Research & Development, Spring House, Pennsylvania.
Corresponding author
  • Casero, Robert A.
  • Zahnow, Cynthia A.
Venue
Cancer Research
Published
2019-07-01
Volume
79
Issue
13
Pages
3445-3454
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2945877868
Cited by
103
References
49
Citations by year
2026: 3 · 2025: 22 · 2024: 9 · 2023: 21 · 2022: 16 · 2021: 18 · 2020: 13 · 2019: 1
FWCI
4.80
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (CA204345, P30CA006973)
  • Samuel Waxman Cancer Research FoundationSamuel Waxman Cancer Research Foundation (SWCRF)
  • Crouse-Irving Memorial HospitalCrouse-Irving Memorial Hospital (Crouse-Irving Hospital)
  • Dr. Miriam and Sheldon G. Adelson Medical Research FoundationDr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)
  • Janssen PharmaceuticalsJanssen Pharmaceuticals (Janssen Pharmaceuticals, Inc.)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
Keywords
ovarian cancer, azacitidine, difluoromethylornithine, M1 macrophages, macrophage polarization, tumor microenvironment, epigenetic therapy, polyamine metabolism, ornithine decarboxylase inhibition, CD4+ T cells, CD8+ T cells, natural killer cells, type I interferon signaling, CSF1R blockade, combination therapy, immunosuppression
MeSH terms
Eflornithine, Animals, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Disease Models, Animal, Female, Immunity, Innate, Macrophages, Mice, Inbred C57BL, Ovarian Neoplasms, Polyamines, Tumor Cells, Cultured, Cystadenocarcinoma, Serous, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-4018
The paper
Travers, M., Brown, S. M., Dunworth, M., Holbert, C. E., Wiehagen, K. R., Bachman, K. E., Foley, J. R., Stone, M. L., Baylin, S. B., Casero, R. A., & Zahnow, C. A. (2019). DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-4018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.